Related Experiment Video
Updated: May 25, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Small molecule kinase inhibitors as anti-cancer therapeutics
O Chahrour1, D Cairns, Z Omran
1School of Pharmacy, University of Damascus, Damascus, Syria.
Mini Reviews in Medicinal Chemistry
|February 7, 2012
Summary
Protein kinase inhibitors are crucial in cancer drug discovery. This review classifies inhibitors by binding site and mechanism, exploring their impact on selectivity and resistance, with a focus on clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Protein kinases are key regulators of cellular processes and significant targets in cancer drug discovery.
- Several kinase inhibitors are FDA-approved, with ongoing research to develop new therapies.
- Understanding inhibitor mechanisms is vital for improving cancer treatment efficacy.
Purpose of the Study:
- To review and classify protein kinase inhibitors based on their mechanisms of action and binding sites.
- To explore the relationship between inhibitor mechanisms, target selectivity, and drug resistance.
- To highlight kinase inhibitors currently undergoing clinical trials for cancer treatment.
Main Methods:
- Literature review and classification of kinase inhibitors.
- Analysis of different inhibitor mechanisms: ATP-competitive, allosteric, substrate-competitive, and covalent inhibitors.
- Examination of clinical trial data for kinase inhibitors.
Main Results:
- Kinase inhibitors can act through various mechanisms, including ATP-competitive and allosteric inhibition.
- Inhibitor classification aids in understanding target selectivity and resistance patterns.
- A significant number of kinase inhibitors are in various phases of clinical trials.
Conclusions:
- The mechanism of action is critical for kinase inhibitor efficacy, selectivity, and overcoming resistance.
- Further research into diverse inhibitor classes and their clinical applications is warranted.
- Targeting protein kinases remains a promising strategy in oncology drug development.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...